# US 2016/0256388 A1 · Compositions and methods for treatment of respiratory tract infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256388 A1
- Document ID: US20160256388A1
- Status: Published application
- Kind: A1
- Application number: 14/998,906
- Filed: 2016-03-02
- Published: 2016-09-08
- Earliest claimed: 2015-03-05
- Assignees: Uri Galili
- Inventors: Uri Galili; Haruko Ogawa
- Web page: https://patentgrep.com/patent/US20160256388A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 39/12: Viral antigens
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention teaches a novel treatment of patients infected with influenza virus in early stages of the disease, with liposomes called α-gal/SA liposomes, in order to decrease the infection period and decrease further complications by this disease. The treatment is based on inhalation of biodegradable liposomes that present two types of carbohydrate epitopes: α-Gal epitopes with the structure Galα1-3Galβ1-4(3)GlcNAc-R) and sialic acid (SA) epitopes. The treatment is based on the ability of influenza virus to bind to SA epitopes and on the binding of the natural anti-Gal antibody (the most abundant natural antibody in humans) to α-gal epitopes. Following inhalation of aerosolized α-gal/SA liposomes they land in the mucus lining the respiratory tract. The α-gal/SA liposomes bind influenza virus via SA epitopes interaction with hemagglutinin of the virus, thus they slow or prevent the progress of the influenza virus infection process. Binding of the natural anti-Gal antibody to α-gal epitopes on α-gal/SA liposomes causes complement mediated chemotactic recruitment of macrophages and dendritic cells which internalize via Fc/Fc receptor interaction the α-gal/SA liposomes and the influenza virus bound to them and destroy this virus. The recruited macrophages and dendritic cells further process the immunogenic peptides of the internalized virus, transported them to the regional lymph nodes and present these peptides for eliciting an effective protective immune response that ends the influenza virus infection in a period shorter than in untreated patients and prevents further complications in the respiratory system and in other parts of the body.

## Claims

### Claim 1

A method for treating respiratory diseases caused by an infectious microbial agent in an animal having endogenous natural antibody, comprising administering by inhalation of liposomes that present both binding receptors to said infectious agent and ligands to said natural antibody wherein:
a) said inhaled liposomes land in mucus and surfactant films coating the respiratory tract epithelium and bind said infectious agent by receptors to said infectious agent on said liposomes,
b) inhalation of said liposomes is under conditions such that binding of infectious agent to corresponding receptor on said liposomes inhibits further infection of respiratory tract epithelium by said infectious agent,
c) inhalation of said liposomes is under conditions such that binding of said natural antibody to said ligands on said inhaled liposomes induces recruitment of granulocytes, monocytes, macrophages and dendritic cells into the respiratory tract of said animal,
d) natural antibody bound to said inhaled liposomes induces internalization of said infectious agent bound to said liposomes into granulocytes, monocytes, macrophages and dendritic cells, and
e) said infectious agent infectious agent internalized into monocytes, macrophages and dendritic cells is processed by these cells to become immunogenic peptides that are transported by these cells to lymph nodes and spleen under conditions that immunogenic peptides induce an effective, protective immune response against said infectious agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein:
a) said ligand binding said natural antibody is selected from the group consisting of terminal non-reducing galactose, glucose, rhamnose, mannose, fucose, N-acetyl-glucosamine, N-acetyl-galactosamine, sialic acid that is N-acetyl-neuraminic acid or N-glycolyl-neuraminic acid,
b) said ligand binding natural antibody and said infectious agent binding receptor on said inhaled liposomes are linked directly or by a linker to a molecule in the liposomes wall which is selected from the group consisting of glycolipids, glycoproteins, proteoglycans, polymers, lipids, or proteins.

### Claim 3 (depends on 1)

The method of claim 1, wherein said natural antibody binding to the inhaled liposomes is the natural anti-Gal antibody and the ligand on the inhaled liposomes that binds the natural anti-Gal antibody is the α-gal epitope, or any epitope capable of binding said natural anti-Gal antibody.

### Claim 4 (depends on 1)

The method in claim 1 in which the ligand on said liposomes for an antibody is immunocomplexed with the corresponding antibody prior to administration by inhalation of said liposomes to treated animal.

### Claim 5 (depends on 1)

The method of claim 1, wherein said animal is selected from the group consisting of birds, mammals and humans.

### Claim 6 (depends on 1)

The method of claim 1 wherein receptors to said infectious agent and said ligand to endogenous natural antibody are both linked to a biodegradable particulate material, or to a molecule from the group of proteins, lipids, proteoglycans, or polymers and used for treatment by inhalation similar to the use of said liposomes.

### Claim 7 (depends on 1, 2, 3, 4)

The method of claims 1, 2, 3 and 4, for the treatment of animals infected in the respiratory tract with influenza virus, wherein:
a) said infectious agent is influenza virus,
b) said infectious agent binding receptor on said inhaled liposomes is selected from the group consisting N-acetyl-neuraminic acid, or N-glycolyl-neuraminic acid, both referred to as sialic acid,
c) said endogenous natural antibody is the anti-Gal antibody, and
d) said ligand to the natural anti-Gal antibody presented on said inhaled liposomes is a glycolipid having a non-reducing end that comprises an α-gal epitope comprising galactosyl α1-3galactosyl, or any other epitope that is capable of binding the natural anti-Gal antibody.

### Claim 8 (depends on 7)

The method in claim 7 for treating a subject infected with influenza virus having endogenous anti-Gal antibody by inhalation of a biodegradable composition of liposomes which present both α-gal epitopes and sialic acid epitopes wherein:
a) influenza virus infecting the respiratory tract binds to said sialic acid epitopes on said inhaled liposomes and is prevented from infecting respiratory epithelium cells,
b) inhalation of said liposomes is under conditions such that the natural anti-Gal antibody binds to said α-gal epitopes on said inhaled liposomes in the respiratory tract,
c) interaction between the natural anti-Gal antibody and α-gal epitopes on said inhaled liposomes is under conditions such that induce recruitment of granulocytes, monocytes, macrophages and dendritic cells to said liposomes,
d) the said recruited granulocytes, monocytes, macrophages and dendritic cells internalize said liposomes and the influenza virus bound to said liposomes,
e) said influenza virus internalized into monocytes, macrophages and dendritic cells is processed by these cells to become immunogenic peptides that are transported to lymph nodes and spleen and that induce an effective, protective immune response against influenza virus.

### Claim 9 (depends on 7, 8)

A method in claims 7 and 8 wherein the treated subject is a human.

### Claim 10 (depends on 7, 8)

A method in claims 7 and 8 wherein the treated subject is selected from groups of apes, Old World monkeys, or birds.